Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
Ranjeet Ajmani, Chief Executive Officer- Asia at Aegros, shared on LinkedIn:
”Plasma-Derived Medicinal Products (PDMPs) are life-saving therapies used to treat a wide range of medical conditions, including immune deficiencies, bleeding disorders, and various rare diseases.
These products are derived from human plasma, which can be collected in two ways: by separating it from donated whole blood (Recovered Plasma) or through a dedicated plasma donation process (Source Plasma).
The manufacturing of PDMPs involves a highly specialized and strictly regulated process called plasma fractionation, where different plasma proteins are separated and purified for therapeutic use.
Since plasma is the primary raw material for these products, ensuring its high quality and safety is of utmost importance.”
Stay informed on all coming webinars and seminars in Hematology with Hemostasis Today.
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List